AUPH - Assessing Aurinia Pharmaceuticals Post FDA Approval

• After nearly two and a half decades, Aurinia Pharmaceuticals' immunosuppressant voclosporin finally garnered FDA approval last week.
• After flunking a Phase 2/3 dry eye syndrome trial in October 2020, voclosporin for lupus nephritis (LN) is the only meaningful asset/indication for the company.
• With voclosporin likely to become the standard of care therapy for LN, a recently inked EU and Japanese collaboration, and insider buying, Aurinia merited a deeper dive.
• A full analysis and recommendation follows below.

For further details see: